Boston Scientific Corporation
BSX
$48.31
-$0.80-1.63%
NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
EPS (TTM)
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.44% | 19.88% | 21.62% | 21.45% | 19.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.44% | 19.88% | 21.62% | 21.45% | 19.35% |
| Cost of Revenue | 15.60% | 18.47% | 23.23% | 23.95% | 21.47% |
| Gross Profit | 18.29% | 20.53% | 20.89% | 20.31% | 18.40% |
| SG&A Expenses | 13.75% | 15.11% | 15.91% | 19.44% | 16.45% |
| Depreciation & Amortization | 5.57% | 4.67% | 6.43% | 3.68% | 2.62% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.37% | 17.15% | 19.47% | 20.75% | 17.46% |
| Operating Income | 26.57% | 32.37% | 31.59% | 24.65% | 28.48% |
| Income Before Tax | 51.01% | 48.29% | 48.34% | 39.88% | 15.26% |
| Income Tax Expenses | -59.69% | 12.84% | 17.15% | 57.37% | 20.42% |
| Earnings from Continuing Operations | 75.84% | 56.66% | 55.56% | 36.82% | 14.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -25.00% | -14.29% | 100.00% | 100.00% | 300.00% |
| Net Income | 75.44% | 56.40% | 55.66% | 36.96% | 14.48% |
| EBIT | 26.57% | 32.37% | 31.59% | 24.65% | 28.48% |
| EBITDA | 21.31% | 25.06% | 24.87% | 19.18% | 21.23% |
| EPS Basic | 74.43% | 55.46% | 54.66% | 36.08% | 14.20% |
| Normalized Basic EPS | 41.50% | 46.28% | 47.43% | 43.44% | 32.09% |
| EPS Diluted | 74.65% | 55.39% | 54.79% | 36.54% | 15.06% |
| Normalized Diluted EPS | 41.74% | 46.32% | 47.29% | 43.20% | 31.77% |
| Average Basic Shares Outstanding | 0.59% | 0.60% | 0.61% | 0.60% | 0.86% |
| Average Diluted Shares Outstanding | 0.42% | 0.58% | 0.71% | 0.78% | 1.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |